Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

28 May, 2021 | 08:27h | UTC

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial – The Lancet Respiratory Medicine

Invited Commentary: Exploiting an early immunological window of opportunity in COVID-19 – The Lancet Respiratory Medicine

 


Lab study found CoronaVac serum neutralization efficiency was significantly decreased against B.1.526, P.1, and B1.351 SARS-CoV-2 variants.

28 May, 2021 | 08:26h | UTC

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac – The Lancet Infectious Diseases

 


RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

28 May, 2021 | 08:24h | UTC

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents – New England Journal of Medicine

Related: [Press release – not published yet] Pfizer-BioNTech vaccine 100% effective against Covid-19 in adolescents

 

Commentary on Twitter

 


RCT: 2 inactivated SARS-CoV-2 vaccines show efficacy of 72.8% and 78.1% on symptomatic COVID-19 infection in adults.

27 May, 2021 | 08:38h | UTC

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial – JAMA

Commentary: China’s Sinopharm Publishes Awaited Covid Vaccine Study Details – Bloomberg

 

Commentary on Twitter (thread – click for more)

 


Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

27 May, 2021 | 08:37h | UTC

Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review – JAMA Network Open

Commentary: Seven out of ten hospitalized COVID-19 patients will have long-haul symptoms – MedicalXpress

 


COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

27 May, 2021 | 08:34h | UTC

COVID Morbidity – Science-Based Medicine

 


[Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19.

27 May, 2021 | 08:31h | UTC

Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients – medRxiv

See also: SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors – EClinicalMedicine

Related: Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

 

Commentaries on Twitter

 


Can people vaccinated against COVID-19 still spread the coronavirus? – “Preliminary evidence seems to suggest the COVID-19 vaccines make it less likely someone who’s vaccinated will transmit the coronavirus”.

27 May, 2021 | 08:27h | UTC

Can people vaccinated against COVID-19 still spread the coronavirus? – The Conversation

Related: Indirect Protection by Reducing Transmission: Ending the Pandemic with SARS-CoV-2 Vaccination – “Tell the hesitant: the vaccines protect both you and protect others — a lot!”

 


Methotrexate reduces immune response to mRNA COVID-19 vaccine in patients with immune-mediated inflammatory disease.

26 May, 2021 | 08:38h | UTC

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease – Annals of Rheumatic Diseases

Commentary: Methotrexate users have a reduced immune response to mRNA COVID-19 vaccine – BMJ

 


Mild COVID-19 induces lasting antibody protection, study finds.

25 May, 2021 | 08:51h | UTC

Mild COVID-19 induces lasting antibody protection, study finds – Washington University School of Medicine

Original study: SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans – Nature

 

Commentary on Twitter (thread – click for more)

 


[Preprint] RCT: Both REGEN-COV 2400mg and 1200mg antibody cocktails significantly reduced Covid-19-related hospitalization or all-cause death compared to placebo (71.3% reduction and 70.4% reduction, respectively).

24 May, 2021 | 08:46h | UTC

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients – medRxiv

 

Commentary on Twitter

 


[Preprint] Pfizer and AstraZeneca Vaccines effective against B.1.617.2 variant after 2 doses.

24 May, 2021 | 08:42h | UTC

News release: Vaccines highly effective against B.1.617.2 variant after 2 doses – Public Health England

Original study: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – Public Health England

Commentary: Covid: Pfizer and AstraZeneca jabs effective against Indian variant – study – BBC

 


Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

24 May, 2021 | 08:38h | UTC

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection – Nature Medicine

Commentary: Scientists find new way of predicting COVID-19 vaccine efficacy – University of New South Wales

 

Commentary on Twitter (thread – click for more)

 


RCT: Among patients with pemphigus vulgaris, rituximab was superior to mycophenolate mofetil in producing sustained complete remission at 52 weeks (40% vs 10%) but was associated with increased risk of serious adverse events (22% vs. 15%).

24 May, 2021 | 08:24h | UTC

Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris – New England Journal of Medicine

 


M-A: In patients with anaphylaxis, the use of multiple epinephrine doses is necessary in 7.7% of cases.

21 May, 2021 | 08:19h | UTC

Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis – The Journal of Allergy and Clinical Immunology

Commentary: How Often Does Anaphylaxis Require Redosing of Epinephrine? – Journal Feed

 


FDA In Brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination.

20 May, 2021 | 08:55h | UTC

FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to Evaluate Immunity or Protection From COVID-19, Including After Vaccination – U.S. Food & Drug Administration

 

Commentary on Twitter (thread – click for more)

 


Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection

20 May, 2021 | 08:52h | UTC

Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection – JAMA Network Open

Editorial: The Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2 Infection—Another Piece of an Expanding Puzzle

Commentary: COVID-related inflammatory syndrome looks different in adults – CIDRAP

 


A pharmacist-led penicillin allergy assessment program can delabel many “penicillin allergic” patients through allergy histories and penicillin skin testing. The program was associated with reduced use of high Clostridioides difficile infection–risk antibiotics.

20 May, 2021 | 08:30h | UTC

Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a Tertiary Care Hospital – JAMA Network Open

 

Commentaries on Twitter

 


WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

19 May, 2021 | 08:47h | UTC

International COVID-19 trial to restart with focus on immune responses – Nature

 


COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.

18 May, 2021 | 07:56h | UTC

COVID vaccines can block variant hitting Asia, lab study finds – Nature

See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress

 

Commentary on Twitter

 


Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.

18 May, 2021 | 07:27h | UTC

Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma – Cochrane Library

Summary: Treatment of gastro-oesophageal reflux disease to help manage asthma in adults and children – Cochrane Library

 


[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.

17 May, 2021 | 08:53h | UTC

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant – The Lancet

News release: Delaying second Pfizer vaccines to 12 weeks significantly increases antibody responses in older people, finds study – University of Birmingham

Commentaries: Delaying a COVID vaccine’s second dose boosts immune response – Nature AND Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds – Health Policy Watch AND Delay in giving second jabs of Pfizer vaccine improves immunity – The Guardian AND Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer-BioNTech COVID-19 vaccine with either a 3-week or a 12-week dosing schedule – Science Media Centre

 


‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.

17 May, 2021 | 08:45h | UTC

‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT

Related: COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization – JAMA Oncology

 


RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

14 May, 2021 | 08:46h | UTC

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data – The Lancet

Commentaries: More side effects noted after using 2 different COVID vaccines – CIDRAP AND Covid vaccines: Mixing increases reports of mild side-effects – BBC

 


Perspective | New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications.

14 May, 2021 | 08:43h | UTC

New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications – New England Journal of Medicine

 


Stay Updated in Your Specialty

No spam, just news.